Research Topics
Species | DAVID TUVESONSummaryAffiliation: University of Pennsylvania Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Technologically advanced cancer modeling in miceDavid A Tuveson
Massachusetts Institute of Technology, Department of Biology and Cancer Center, and Howard Hughes Medical Institute, 40 Ames Street, Cambridge, Massachusetts 02139, USA
Curr Opin Genet Dev 12:105-10. 2002..The murine tumor models are beginning to reveal mysteries of tumorigenesis, such as the role of the tumor microenvironment and the dependence of tumors on continuous oncogenic stimulation...- ATP citrate lyase inhibition can suppress tumor cell growthGeorgia Hatzivassiliou
Department of Cancer Biology, Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA 19104, USA
Cancer Cell 8:311-21. 2005..ACL inhibition by RNAi or the chemical inhibitor SB-204990 limits in vitro proliferation and survival of tumor cells displaying aerobic glycolysis. The same treatments also reduce in vivo tumor growth and induce differentiation... - Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinomaDavid A Tuveson
Department of Medicine, Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania, USA
Cancer Res 66:242-7. 2006..These findings suggest that Mist1-expressing cells represent a permissive compartment for transformation by oncogenic Kras in pancreatic tumorigenesis... - BRAF as a potential therapeutic target in melanoma and other malignanciesDavid A Tuveson
Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Cancer Cell 4:95-8. 2003 - The differential effects of mutant p53 alleles on advanced murine lung cancerErica L Jackson
Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02141, USA
Cancer Res 65:10280-8. 2005..In contrast to the lung tumors, expression of the point-mutant p53 alleles strongly promoted the development of sinonasal adenocarcinomas compared with simple loss-of-function, suggesting a tissue-specific gain-of-function... - Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivoBenjamin S Braun
Department of Pediatrics, HSE 302, University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA
Blood 108:2041-4. 2006.... - The use of targeted mouse models for preclinical testing of novel cancer therapeuticsKenneth P Olive
Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Clin Cancer Res 12:5277-87. 2006.... - Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885Alastair J King
Department of Oncology, MMPD CEDD, GlaxoSmithKline, Collegeville, Pennsylvania 19426, USA
Cancer Res 66:11100-5. 2006.... - Restoration of p53 function leads to tumour regression in vivoAndrea Ventura
Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA
Nature 445:661-5. 2007..These results support efforts to treat human cancers by way of pharmacological reactivation of p53... - Expression of oncogenic K-ras from its endogenous promoter leads to a partial block of erythroid differentiation and hyperactivation of cytokine-dependent signaling pathwaysJing Zhang
Whitehead Institute for Biomedical Research, Cambridge, MA, USA
Blood 109:5238-41. 2007..Our results support efforts to modulate Ras signaling for treating hematopoietic malignancies... - Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreasKamel Izeradjene
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Cancer Cell 11:229-43. 2007..Our findings suggest that the sequence, as well as the context, in which these critical mutations are acquired helps determine the ensuing pathology... - Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesisAlice T Shaw
Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, and Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston 02114, USA
Genes Dev 21:694-707. 2007..These findings indicate that in the lung, Sprouty-2 plays a critical role in the regulation of oncogenic K-ras, and implicate counter-regulatory mechanisms in the pathogenesis of Ras-based disease... - The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progressionRyan M Thomas
Division of Surgical Oncology, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
Cancer Res 67:6075-82. 2007..Taken together, these findings suggest that RON receptor signaling may contribute to pancreatic carcinogenesis, and that further investigation is warranted to assess the potential of RON-directed therapies in this deadly disease... - Maximizing mouse cancer modelsKristopher K Frese
Cambridge Research Institute, Cancer Research UK
Nat Rev Cancer 7:645-58. 2007.... - Requirement for Rac1 in a K-ras induced lung cancer in the mouseJoseph L Kissil
Program in Molecular Oncogenesis, The Wistar Institute, Philadelphia, PA 19104, USA
Cancer Res 67:8089-94. 2007..These data show a specific requirement for Rac1 function in cells expressing oncogenic K-ras... - Dynamics of the immune reaction to pancreatic cancer from inception to invasionCAROLYN E CLARK
Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Cancer Res 67:9518-27. 2007..Efforts to test potent inhibitors of MDSC, tumor-associated macrophages, and Treg, particularly early in the disease represent important next steps for developing novel immunotherapy of cancer... - Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer developmentSusan W P Wijnhoven
Laboratory of Toxicology, Pathology and Genetics, National Institute of Public Health and the Environment, Bilthoven, The Netherlands
Cancer Res 65:8166-73. 2005..As such, p53(R270H/+)WAPCre mice provide a well-suited model system to study the role of p53 in breast tumorigenesis and the responsiveness of mammary gland tumors to chemotherapeutics... - VAV1: a new target in pancreatic cancer?Gina Denicola
Department of Cancer Biology, Abramson Family Cancer Research Institute, The Abramson Cancer Center at the University of Pennsylvania Medical Center, Philadelphia, PA, USA
Cancer Biol Ther 4:509-11. 2005..This study provides the first evidence of VAV1 promoter demethylation as an event in cancer progression, suggesting that aberrant signaling pathways driven by VAV1 are potential therapeutic targets in PDA... - Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumorsGeorge D Demetri
Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA 02115, USA
N Engl J Med 347:472-80. 2002..Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy... - Ras redux: rethinking how and where Ras actsSunil R Hingorani
Abramson Family Cancer Research Institute, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Curr Opin Genet Dev 13:6-13. 2003..Recent findings have provided new and unexpected insights into the predominant pathways Ras employs to transform human cells and the subcellular platforms from which it can act... - In search of an early warning system for pancreatic cancerSunil R Hingorani
Departments of Cancer Biology and Medicine, Abromson Family Cancer Research Institute, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
Cancer Biol Ther 2:84-6. 2003 - Targeting oncogene dependence and resistanceSunil R Hingorani
Abramson Family Cancer Research Institute, Abramson Cancer Center of the University of Pennsylvania School of Medicine, Department of Medicine, Philadelphia 19104, USA
Cancer Cell 3:414-7. 2003..Recent findings reveal several mechanisms of resistance and suggest ways to overcome them... - Suppression of BRAF(V599E) in human melanoma abrogates transformationSunil R Hingorani
Abramson Family Cancer Research Institute at the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Cancer Res 63:5198-202. 2003..Thus, when present, BRAF(V599E) appears to be essential for melanoma cell viability and transformation and, therefore, represents an attractive therapeutic target in the majority of melanomas that harbor the mutation... - Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinomaAndrew J Aguirre
Department of Medical Oncology, Dana Farber Cancer Institute and Department of Genetics, Harvard Medical School, Boston, MA 02115, USA
Genes Dev 17:3112-26. 2003..This faithful mouse model may permit the systematic analysis of genetic lesions implicated in the human disease and serve as a platform for the identification of early disease markers and for the efficient testing of novel therapies... - Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouseSunil R Hingorani
Department of Medicine, Abramson Family Cancer Research Institute, Abramson Center at the University of Pennsylvania, Philadelphia, PA 19104, USA
Cancer Cell 4:437-50. 2003..Finally, mice with PanINs have an identifiable serum proteomic signature, suggesting a means of detecting the preinvasive state in patients... - Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative diseaseIris T Chan
Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
J Clin Invest 113:528-38. 2004..This model system will be useful for assessing the contribution of cooperating mutations in AML and testing ras inhibitors in vivo... - Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defectsDavid A Tuveson
Abramson Family Cancer Research Institute, Abramson Cancer Center and Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104 USA
Cancer Cell 5:375-87. 2004..Our results suggest that endogenous oncogenic ras is sufficient to initiate transformation by stimulating proliferation, while further genetic lesions may be necessary for progression to frank malignancy... - Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in miceSunil R Hingorani
Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Cancer Cell 7:469-83. 2005..These findings have clear implications for understanding mechanisms of disease pathogenesis, and for the development of detection and targeted treatment strategies... - Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumorsArati Sharma
Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey 17033, USA
Cancer Res 65:2412-21. 2005..Thus, these studies identify the mechanistic underpinnings by which mutant (V599E)B-RAF promotes melanoma development and show the effectiveness of targeting this protein to inhibit melanoma tumor growth... - K-Ras-driven pancreatic cancer mouse model for anticancer inhibitor analysesNatalie Cook
Department of Clinical Oncology, Addenbrookes NHS Trust, Cambridge, United Kingdom
Methods Enzymol 439:73-85. 2008..We hypothesize that results of our preclinical studies will inform the design of clinical trials for pancreatic cancer patients... - Mutant p53 gain of function in two mouse models of Li-Fraumeni syndromeKenneth P Olive
Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
Cell 119:847-60. 2004..These results demonstrate that point mutant p53 alleles expressed under physiological control have enhanced oncogenic potential beyond the simple loss of p53 function... - Detecting and diagnosing ampullary neoplasmsLi-Fu Wang
Departments of Cancer Biology and Medicine, Abramson Family Cancer Research Institute, The Abramson Cancer Center at the University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
Cancer Biol Ther 3:657-9. 2004 - Twist induces an epithelial-mesenchymal transition to facilitate tumor metastasisFlorian Karreth
Department of Cancer Biology, Abramson Family Cancer Research Institute, The Abramson Cancer Center at the University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
Cancer Biol Ther 3:1058-9. 2004..This study provides direct evidence that EMT may be an essential process during metastasis and should appropriately stimulate further investigations of EMT in many laboratories... - Pancreatic cancer in mice and man: the Penn Workshop 2004Ralph H Hruban
Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Cancer Res 66:14-7. 2006..The working groups presented their reports on the final day of the conference, and highlights of selected individual presentations and working group recommendations are summarized here and in an accompanying pathology consensus report... - Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorderBenjamin S Braun
Department of Pediatrics, University of California, San Francisco, CA 94143, USA
Proc Natl Acad Sci U S A 101:597-602. 2004..Oncogenic RAS is sufficient to initiate myeloid leukemogenesis in mice, and this provides an in vivo system for biologic and preclinical studies... - Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendationsRalph H Hruban
Department of Pathology, The Sol Goldman Center for Pancreatic Cancer Research, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
Cancer Res 66:95-106. 2006....
Research Grants
- Mutant mouse models of exocrine pancreatic cancerDAVID TUVESON; Fiscal Year: 2006..Information gained from this murine model should facilitate further understanding of human pancreatic cancer. ..
- Mutant mouse models of exocrine pancreatic cancerDAVID TUVESON; Fiscal Year: 2007..Information gained from this murine model should facilitate further understanding of human pancreatic cancer. ..